Mylan said Colazal capsules, which treats mild to moderate ulcerative colitis, had U.S. sales of about $130.9 million for the 12 months ending September 30.
(Reuters) - Drug maker Mylan Inc <MYL.N> said its generic version of Salix Pharmaceuticals Ltd's <SLXP.O> Colazal capsules received final regulatory approval.
Mylan said Colazal capsules, which treats mild to moderate ulcerative colitis, had U.S. sales of about $130.9 million for the 12 months ending September 30.
Mylan said in a statement its product will be shipped immediately.
(Reporting by Shamik Paul in Bangalore)
!ADVERTISEMENT!
